Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 4Squamous Cell Carcinoma of Head and Neck 2Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasms 2Lymphoproliferative Disorders 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Melanoma 1Lymphoid Interstitial Pneumonia 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Extensive Stage Lung Small Cell Carcinoma 1Endometrial Neoplasms 1Carcinoma 1Advanced Solid Tumor 1

Interventions

atezolizumab 1Specimen Handling 1Radiotherapy 1Radiation 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Extensive Stage Lung Small Cell Carcinoma × atezolizumab × Clear all
NCT04402788 2026-06-02

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
138 enrolled

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡